Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT06669572
Title Lenvatinib and Pembrolizumab to Treat Patients With Anal or Rectum Cancer That Has Gotten Worse After Initial Treatment
Recruitment Not yet recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors University of Chicago
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA

Facility Status City State Zip Country Details
o University of Chicago Medicine Comprehensive Cancer Center Chicago Illinois 60637 United States Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field